Tumor Necrosis Factor Inhibitor Drugs Market - Top Companies and Manufacturers

  • Report ID: 6538
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Companies Dominating the Tumor Necrosis Factor Inhibitor Drugs Landscape

    The tumor necrosis factor inhibitor drugs market is characterized by a dynamic and fiercely competitive environment, with both well-established pharmaceutical giants and cutting-edge biotechnology companies driving the industry. The market is dominated by major firms such as AbbVie and Pfizer due to their brand recognition and a wealth of clinical data proving the medications' safety and efficacy. The competition is being heightened by more recent entrants, such as firms creating biosimilars and next-generation TNF inhibitors, providing more affordable options and maybe better therapeutic characteristics. Further altering the market is the continued focus of research and development on enhancing the selectivity and minimizing the adverse effects of TNF inhibitors.

    Here are some leading players in the tumor necrosis factor inhibitor drugs market:

    • CVS Health
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Amgen Inc.
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Bio-Thera Solutions, Ltd.
    • Janssen Biotech, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Samsung Bioepis Co., Ltd.
    • Sandoz Group AG
    • UCB, Inc.

Browse Key Market Insights with Data Illustration:

In the News

  • In May 2023, Boehringer Ingelheim received U.S. FDA approval for Cyltezo Pen, a novel autoinjector developed for treating chronic inflammatory diseases.
  • In January 2023, Amgen announced the launch of Amjevita, the first biosimilar to Humira to treat serious inflammatory disorders. This drug will be available in prefilled syringes and autoinjector presentations.

Author Credits:  Radhika Pawar


  • Report ID: 6538
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The tumor necrosis factor inhibitor drugs market size was USD 42.9 billion in 2024.

The global tumor necrosis factor inhibitor drugs market size was US 42.9 billion in 2024 and is likely to reach USD 59.4 billion by the end of 2037, expanding at a CAGR of 2.5% over the forecast period, i.e., 2025-2037.

Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bio-Thera Solutions, Ltd., Janssen Biotech, Inc., Merck & Co., Inc., Pfizer Inc., Samsung Bioepis Co., Ltd., Sandoz Group AG, UCB, Inc. are some key players in the market.

The adalimumab segment is expected to hold a leading share during the forecast period.

North America is projected to offer lucrative prospects with a share of 38.6% during the forecast period.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample